• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 15, 2021

View Archived Issues
Polycythemia vera illustration

Pharmaessentia’s Besremi approved in US for rare blood disorder polycythemia vera

The FDA has approved Pharmaessentia Corp.'s Besremi (ropeginterferon alfa-2b) for the rare blood disorder polycythemia vera, the interferon offering an alternative to JAK inhibitor therapy. PV is a rare, chronic and life-threatening blood cancer caused by a mutation in stem cells in the bone marrow, resulting in overproduction of blood cells. Besremi, which is already approved in Taiwan, Europe and South Korea, is a monopegylated, long-acting interferon, which counteracts the effects of the mutated bone marrow cells and is initially taken fortnightly. Read More

STATute of limitations? Time running out for ‘undruggable’ SH2 as Recludix bags $60M series A

Recludix Pharma Inc. launched with a $60 million series A round to target Src homology 2 (SH2) domains, and the new money will get the San Diego-based firm to reach the IND-enabling stage, CEO Nancy Whiting told BioWorld. Read More
Grey dollar sign on grey background

Ankyra Therapeutics raises $45M series B to advance cytokine immunotherapies

Ankyra Therapeutics Inc., a company developing new cytokine immunotherapies to boost localized antitumor immune responses, closed a $45 million series B financing. Proceeds from the round will be used to advance the Boston-based company's lead molecule, ANK-101, through IND-enabling studies and into phase I trials starting at the beginning of 2023, as well as to advance additional cytokine programs, it said. Read More

Valo prepping for phase I cancer study, looking to IPO in 2022

LONDON – Cancer immunotherapy specialist Valo Therapeutics Oy has raised €11 million (US$12.6 million) in an oversubscribed round that will fund the final preparations to move the lead program into the clinic at the start of 2022, and to prepare for an IPO later next year. The phase I will be the first test in humans of Valo’s Pepticrad (peptide-coated conditionally replicating adenovirus technology), which combines two different approaches for which there is there is separate clinical proof: oncolytic adenoviruses and peptide cancer vaccines. Read More
Clinical research concept with medical icons on light bulb

Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets

LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small molecules aimed at intractable and poorly drugged membrane and complex-bound protein targets. The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute carriers, are relevant to immunology indications and rare diseases with high unmet need. Read More
ICYMI illustration

ICYMI: Week in review, Nov. 8-12, 2021

A quick look back at top stories. Read More

Appointments and advancements for Nov. 15, 2021

New hires and promotions in the biopharma industry, including: Alchemab, Autolus, Biogencell, Catamaran, Coave, Coimmune, Diurnal, Nektar, Oblique, Oncopeptides, Rani, Valo. Read More

Conference data for Nov. 15, 2021: AASLD

New and updated preclinical and clinical data presented by biopharma firms at The Liver Meeting of the American Association for the Study of Liver Diseases, including: 89bio, Akero, Cymabay, Intercept, Protagonist, Sagimet, Surrozen, Versantis. Read More

Conference data for Nov. 15, 2021: SITC

New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including: Antengene, Carisma, Celularity, CG Oncology. Read More

Financings for Nov. 15, 2021

Biopharmas raising money in public or private financings, including: Acelrx, Athos, Bioplus, Cognition, Intensity, Pear, Tricida. Read More

In the clinic for Nov. 15, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abionyx, AC Immune, Addex, AGTC, Akero, Albireo, Alnylam, Anaptysbio, Annovis, Appili, Arrowhead, Assembly, Astrazeneca, Aura, Bioarctic, Biogen, Biophytis, Biosight, BMS, Catalym, Clene, Cytovation, Dicerna, Eisai, Emergex, Enanta, Eyepoint, GSK, Inflarx, Innovent, Inozyme, Intensity, Janssen, Kintor, Madrigal, Moderna, Newamsterdam, Nikang, Nimbus, Oculis, Oxurion, Pierre Fabre, Recbio, Redhill, Redx, Regenxbio, Revelation, Ribomic, Rocket, Sagimet, Sorrento, Terns, Vaccitech, Vir. Read More

Other news to note for Nov. 15, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Aditum, Antios, Bioarctic, BioMarin, Combangio, Entos, Eton, Irbm, Kala, Lowell, Motorpharma, Motric, Newsoara, Revelar, Rigel, Tolmar, Twist, Valbiotis, Zenith. Read More

Regulatory actions for Nov. 15, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Apellis, Ascendis, Beigene, Carsgen, Celltrion, Chemocentryx, Coherus, Eli Lilly, Galapagos, Gannex, Hebabiz, Hyloris, Innocare, Junshi, Kyowa Kirin, Mimivax, Moderna, Newbridge, Novavax, Novo, Nrx, Nurix, Pharmaessentia, Regeneron, Relief, Rhythm, Roche, Sanofi, SK Bioscience, Vertex, Viridian. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 21, 2025.
  • Illustration of antibodies attacking the thyroid

    Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders

    BioWorld Science
    Graves disease (GD)-associated hyperthyroidism is an autoimmune disorder characterized by the presence of autoantibodies that stimulate the thyroid-stimulating...
  • Illustration of cancer cells entering the bloodstream.

    TIM3 blockade could halt breast cancer before it spreads

    BioWorld Science
    In the current landscape of cancer research, much attention is focused on the tumor microenvironment (TME) at both the primary site and established metastases....
  • Lungs

    Still no scare for Ohtuvayre: Roche IL-33 COPD data mixed

    BioWorld
    The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe